RU2201919C2 - Стирилсульфоновые соединения, фармацевтические композиции на их основе, способ ингибирования роста опухолевых клеток, способ индукции апоптоза опухолевых клеток и способ лечения - Google Patents
Стирилсульфоновые соединения, фармацевтические композиции на их основе, способ ингибирования роста опухолевых клеток, способ индукции апоптоза опухолевых клеток и способ лечения Download PDFInfo
- Publication number
- RU2201919C2 RU2201919C2 RU2000111513/04A RU2000111513A RU2201919C2 RU 2201919 C2 RU2201919 C2 RU 2201919C2 RU 2000111513/04 A RU2000111513/04 A RU 2000111513/04A RU 2000111513 A RU2000111513 A RU 2000111513A RU 2201919 C2 RU2201919 C2 RU 2201919C2
- Authority
- RU
- Russia
- Prior art keywords
- compound
- cells
- styryl
- composition
- tumor cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 78
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 42
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 230000005764 inhibitory process Effects 0.000 title abstract description 5
- XJNHONCWGODPIZ-PHEQNACWSA-N [(e)-2-[(e)-2-phenylethenyl]sulfonylethenyl]benzene Chemical class C=1C=CC=CC=1/C=C/S(=O)(=O)\C=C\C1=CC=CC=C1 XJNHONCWGODPIZ-PHEQNACWSA-N 0.000 title abstract description 4
- 230000006698 induction Effects 0.000 title abstract description 3
- 230000004565 tumor cell growth Effects 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 135
- 150000001875 compounds Chemical class 0.000 claims abstract description 126
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 29
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 24
- 208000023958 prostate neoplasm Diseases 0.000 claims abstract description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 21
- 239000001257 hydrogen Substances 0.000 claims abstract description 21
- 210000000481 breast Anatomy 0.000 claims abstract description 17
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 13
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000460 chlorine Substances 0.000 claims abstract description 11
- 239000011737 fluorine Substances 0.000 claims abstract description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 239000003937 drug carrier Substances 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- -1 chloro, fluoro, bromo, methyl Chemical group 0.000 claims description 9
- 210000002307 prostate Anatomy 0.000 claims description 9
- ZDYHTOFOTBKCFQ-MDZDMXLPSA-N 1-bromo-4-[[(e)-2-(4-chlorophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(Cl)=CC=C1\C=C\S(=O)(=O)CC1=CC=C(Br)C=C1 ZDYHTOFOTBKCFQ-MDZDMXLPSA-N 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000001246 bromo group Chemical group Br* 0.000 claims description 6
- 230000010261 cell growth Effects 0.000 claims description 6
- CHQQDELDVCBHKN-MDZDMXLPSA-N 1-bromo-4-[[(e)-2-(4-fluorophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(F)=CC=C1\C=C\S(=O)(=O)CC1=CC=C(Br)C=C1 CHQQDELDVCBHKN-MDZDMXLPSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- JJSHRTVHJFKOFB-MDZDMXLPSA-N 1-[[(e)-2-(4-bromophenyl)ethenyl]sulfonylmethyl]-4-chlorobenzene Chemical compound C1=CC(Cl)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(Br)C=C1 JJSHRTVHJFKOFB-MDZDMXLPSA-N 0.000 claims description 4
- URBLDUHDENNTET-MDZDMXLPSA-N 1-[[(e)-2-(4-bromophenyl)ethenyl]sulfonylmethyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(Br)C=C1 URBLDUHDENNTET-MDZDMXLPSA-N 0.000 claims description 4
- NXLVMMFSYHOBNA-BQYQJAHWSA-N 2,4-difluoro-1-[(e)-2-[(4-fluorophenyl)methylsulfonyl]ethenyl]benzene Chemical compound C1=CC(F)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(F)C=C1F NXLVMMFSYHOBNA-BQYQJAHWSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- BPCWSTIDUJXABN-MDZDMXLPSA-N 1-bromo-4-[[(e)-2-(4-bromophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(Br)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(Br)C=C1 BPCWSTIDUJXABN-MDZDMXLPSA-N 0.000 claims description 3
- GMKXPTFOBQFAOD-MDZDMXLPSA-N 1-chloro-4-[[(e)-2-(4-fluorophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(F)=CC=C1\C=C\S(=O)(=O)CC1=CC=C(Cl)C=C1 GMKXPTFOBQFAOD-MDZDMXLPSA-N 0.000 claims description 3
- QFXKVNVCBJMHBH-MDZDMXLPSA-N 1-fluoro-4-[[(e)-2-(4-fluorophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(F)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(F)C=C1 QFXKVNVCBJMHBH-MDZDMXLPSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- RPDRBEJDYHVLME-ZHACJKMWSA-N 1-[(e)-2-(benzenesulfonyl)ethenyl]-4-bromobenzene Chemical compound C1=CC(Br)=CC=C1\C=C\S(=O)(=O)C1=CC=CC=C1 RPDRBEJDYHVLME-ZHACJKMWSA-N 0.000 claims description 2
- HVSMMGMOGXMVNZ-MDZDMXLPSA-N 1-bromo-4-[(e)-2-(4-chlorophenyl)sulfonylethenyl]benzene Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)\C=C\C1=CC=C(Br)C=C1 HVSMMGMOGXMVNZ-MDZDMXLPSA-N 0.000 claims description 2
- BHZSVOGMDVLRRR-MDZDMXLPSA-N 1-chloro-4-[(e)-2-(4-chlorophenyl)sulfonylethenyl]benzene Chemical compound C1=CC(Cl)=CC=C1\C=C\S(=O)(=O)C1=CC=C(Cl)C=C1 BHZSVOGMDVLRRR-MDZDMXLPSA-N 0.000 claims description 2
- WXVZZCHUAIGQKJ-MDZDMXLPSA-N 1-chloro-4-[[(e)-2-(4-chlorophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(Cl)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(Cl)C=C1 WXVZZCHUAIGQKJ-MDZDMXLPSA-N 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 230000017095 negative regulation of cell growth Effects 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims 5
- 230000006882 induction of apoptosis Effects 0.000 claims 3
- 201000001514 prostate carcinoma Diseases 0.000 claims 3
- DUEHAQMOFFMCKG-PHEQNACWSA-N FC1(CC(=C(CS(=O)(=O)CC2=C(CC(C=C2)(F)Cl)\C=C\C2=CC=CC=C2)C=C1)\C=C\C1=CC=CC=C1)Cl Chemical compound FC1(CC(=C(CS(=O)(=O)CC2=C(CC(C=C2)(F)Cl)\C=C\C2=CC=CC=C2)C=C1)\C=C\C1=CC=CC=C1)Cl DUEHAQMOFFMCKG-PHEQNACWSA-N 0.000 claims 2
- LRHCIAKITMHSNT-OGBZJDJUSA-N 1-[(e)-3-(4-chlorophenyl)-3-[(e)-1-(4-chlorophenyl)-3-(4-fluorophenyl)prop-2-enyl]sulfonylprop-1-enyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C=CC(F)=CC=1)C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 LRHCIAKITMHSNT-OGBZJDJUSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 45
- 239000003814 drug Substances 0.000 abstract description 14
- 230000035755 proliferation Effects 0.000 abstract description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 44
- 230000015572 biosynthetic process Effects 0.000 description 37
- 238000003786 synthesis reaction Methods 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 24
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 23
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 18
- 102000043136 MAP kinase family Human genes 0.000 description 17
- 108091054455 MAP kinase family Proteins 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 12
- 239000006166 lysate Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 239000003098 androgen Substances 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 239000001045 blue dye Substances 0.000 description 8
- 230000007717 exclusion Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- WCOXFTGMNJJABC-SREVYHEPSA-N 2-[(z)-2-phenylethenyl]sulfonylacetic acid Chemical compound OC(=O)CS(=O)(=O)\C=C/C1=CC=CC=C1 WCOXFTGMNJJABC-SREVYHEPSA-N 0.000 description 7
- HPWAJMXOEYIERK-UHFFFAOYSA-N 2-benzylsulfonylacetic acid Chemical class OC(=O)CS(=O)(=O)CC1=CC=CC=C1 HPWAJMXOEYIERK-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 150000003934 aromatic aldehydes Chemical class 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 6
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 6
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000012047 saturated solution Substances 0.000 description 6
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- XJNHONCWGODPIZ-AOGCGKDYSA-N 2-[(e)-2-phenylethenyl]sulfonylethenylbenzene Chemical class C=1C=CC=CC=1/C=C/S(=O)(=O)C=CC1=CC=CC=C1 XJNHONCWGODPIZ-AOGCGKDYSA-N 0.000 description 5
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- IAONCYGNBVHNCT-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfonylacetic acid Chemical compound OC(=O)CS(=O)(=O)C1=CC=C(Cl)C=C1 IAONCYGNBVHNCT-UHFFFAOYSA-N 0.000 description 4
- YTEFAALYDTWTLB-UHFFFAOYSA-N 2-(benzenesulfonyl)acetic acid Chemical compound OC(=O)CS(=O)(=O)C1=CC=CC=C1 YTEFAALYDTWTLB-UHFFFAOYSA-N 0.000 description 4
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 4
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 4
- 229940106681 chloroacetic acid Drugs 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- WDYRPTWUNMHTJL-UHFFFAOYSA-N 2-(carboxymethylsulfonyl)acetic acid Chemical compound OC(=O)CS(=O)(=O)CC(O)=O WDYRPTWUNMHTJL-UHFFFAOYSA-N 0.000 description 3
- VMYFZBLZKJJKLR-UHFFFAOYSA-N 2-[(4-bromophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(Br)C=C1 VMYFZBLZKJJKLR-UHFFFAOYSA-N 0.000 description 3
- YYXBXAYHHCTPEF-UHFFFAOYSA-N 2-[(4-chlorophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(Cl)C=C1 YYXBXAYHHCTPEF-UHFFFAOYSA-N 0.000 description 3
- STQLDAZMDJUSKV-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(F)C=C1 STQLDAZMDJUSKV-UHFFFAOYSA-N 0.000 description 3
- XJNHONCWGODPIZ-CSXFVWEESA-N 2-[(Z)-2-phenylethenyl]sulfonylethenylbenzene Chemical class C(=C/C1=CC=CC=C1)/S(=O)(=O)C=CC1=CC=CC=C1 XJNHONCWGODPIZ-CSXFVWEESA-N 0.000 description 3
- SEUYMUDVXBSSGT-UHFFFAOYSA-N 4-phenylbut-3-enethioic s-acid Chemical compound SC(=O)CC=CC1=CC=CC=C1 SEUYMUDVXBSSGT-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000010337 G2 phase Effects 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- MRTIWTGAGMZREP-QXMHVHEDSA-N [(z)-2-phenylethenyl]sulfonylmethylbenzene Chemical class C=1C=CC=CC=1\C=C/S(=O)(=O)CC1=CC=CC=C1 MRTIWTGAGMZREP-QXMHVHEDSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- SYTHOKWALOYRAP-UHFFFAOYSA-N 2-[2-chloro-3-(2-chloro-3-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C1=CC=C(S(=O)(=O)C=2C(=C(CC(=O)C=3C=CC=CC=3)C=CC=2)Cl)C(Cl)=C1CC(=O)C1=CC=CC=C1 SYTHOKWALOYRAP-UHFFFAOYSA-N 0.000 description 2
- JXHLDZVRNMLMEB-UHFFFAOYSA-N 2-[5-fluoro-2-(4-fluoro-2-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C=1C(F)=CC=C(S(=O)(=O)C=2C(=CC(F)=CC=2)CC(=O)C=2C=CC=CC=2)C=1CC(=O)C1=CC=CC=C1 JXHLDZVRNMLMEB-UHFFFAOYSA-N 0.000 description 2
- 101100397594 Ancylostoma caninum JNK-1 gene Proteins 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 2
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 description 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 2
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 description 2
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 2
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- AWHNUHMUCGRKRA-UHFFFAOYSA-N benzylsulfonylmethylbenzene Chemical class C=1C=CC=CC=1CS(=O)(=O)CC1=CC=CC=C1 AWHNUHMUCGRKRA-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 230000021953 cytokinesis Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 2
- 229940046307 sodium thioglycolate Drugs 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- GMZMXCZTVDOYNX-ZHACJKMWSA-N 1-[(e)-2-(4-chlorophenyl)sulfonylethenyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1\C=C\S(=O)(=O)C1=CC=C(Cl)C=C1 GMZMXCZTVDOYNX-ZHACJKMWSA-N 0.000 description 1
- LUFVQVKHWIYXIB-ZHACJKMWSA-N 1-[(e)-2-(4-chlorophenyl)sulfonylethenyl]-4-methylbenzene Chemical compound C1=CC(C)=CC=C1\C=C\S(=O)(=O)C1=CC=C(Cl)C=C1 LUFVQVKHWIYXIB-ZHACJKMWSA-N 0.000 description 1
- QPMFUCLWWAQPBD-CMDGGOBGSA-N 1-[(e)-2-(benzenesulfonyl)ethenyl]-2,4-dichlorobenzene Chemical compound ClC1=CC(Cl)=CC=C1\C=C\S(=O)(=O)C1=CC=CC=C1 QPMFUCLWWAQPBD-CMDGGOBGSA-N 0.000 description 1
- FXYBLJJXHQXMTH-ZHACJKMWSA-N 1-[(e)-2-(benzenesulfonyl)ethenyl]-4-chlorobenzene Chemical compound C1=CC(Cl)=CC=C1\C=C\S(=O)(=O)C1=CC=CC=C1 FXYBLJJXHQXMTH-ZHACJKMWSA-N 0.000 description 1
- YMRHRTUPMUIKBX-ZHACJKMWSA-N 1-[(e)-2-benzylsulfonylethenyl]-2-chlorobenzene Chemical compound ClC1=CC=CC=C1\C=C\S(=O)(=O)CC1=CC=CC=C1 YMRHRTUPMUIKBX-ZHACJKMWSA-N 0.000 description 1
- CQQMYELYPHEXMW-ZHACJKMWSA-N 1-[(e)-2-benzylsulfonylethenyl]-4-chlorobenzene Chemical compound C1=CC(Cl)=CC=C1\C=C\S(=O)(=O)CC1=CC=CC=C1 CQQMYELYPHEXMW-ZHACJKMWSA-N 0.000 description 1
- YSFBEAASFUWWHU-UHFFFAOYSA-N 2,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C(Cl)=C1 YSFBEAASFUWWHU-UHFFFAOYSA-N 0.000 description 1
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 1
- RAFWRUNTUFYFAC-UHFFFAOYSA-N 2-(2-chlorophenyl)sulfonyl-3-(4-fluorophenyl)-1-phenylprop-2-en-1-one Chemical compound C1=CC(F)=CC=C1C=C(S(=O)(=O)C=1C(=CC=CC=1)Cl)C(=O)C1=CC=CC=C1 RAFWRUNTUFYFAC-UHFFFAOYSA-N 0.000 description 1
- WCOXFTGMNJJABC-UHFFFAOYSA-N 2-(2-phenylethenylsulfonyl)acetic acid Chemical compound OC(=O)CS(=O)(=O)C=CC1=CC=CC=C1 WCOXFTGMNJJABC-UHFFFAOYSA-N 0.000 description 1
- DREVPGKOIZVPQV-UHFFFAOYSA-N 2-(benzenesulfonyl)-1-phenylethanone Chemical compound C=1C=CC=CC=1C(=O)CS(=O)(=O)C1=CC=CC=C1 DREVPGKOIZVPQV-UHFFFAOYSA-N 0.000 description 1
- RIUCTGMEDZCYKZ-UHFFFAOYSA-N 2-[2-nitro-3-(2-nitro-3-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C1=CC=C(S(=O)(=O)C=2C(=C(CC(=O)C=3C=CC=CC=3)C=CC=2)[N+]([O-])=O)C([N+](=O)[O-])=C1CC(=O)C1=CC=CC=C1 RIUCTGMEDZCYKZ-UHFFFAOYSA-N 0.000 description 1
- DSNUPUMBSSCFHS-UHFFFAOYSA-N 2-[5-bromo-2-(4-bromo-2-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C=1C(Br)=CC=C(S(=O)(=O)C=2C(=CC(Br)=CC=2)CC(=O)C=2C=CC=CC=2)C=1CC(=O)C1=CC=CC=C1 DSNUPUMBSSCFHS-UHFFFAOYSA-N 0.000 description 1
- WXBWJTDIRGOOAN-UHFFFAOYSA-N 2-[5-chloro-2-(4-chloro-2-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C=1C(Cl)=CC=C(S(=O)(=O)C=2C(=CC(Cl)=CC=2)CC(=O)C=2C=CC=CC=2)C=1CC(=O)C1=CC=CC=C1 WXBWJTDIRGOOAN-UHFFFAOYSA-N 0.000 description 1
- AMJUCPMWRHEFEO-UHFFFAOYSA-N 2-[5-methoxy-2-(4-methoxy-2-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C=1C(OC)=CC=C(S(=O)(=O)C=2C(=CC(OC)=CC=2)CC(=O)C=2C=CC=CC=2)C=1CC(=O)C1=CC=CC=C1 AMJUCPMWRHEFEO-UHFFFAOYSA-N 0.000 description 1
- YPAMEUJNJVCLNP-UHFFFAOYSA-N 2-[5-nitro-2-(4-nitro-2-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C=1C([N+](=O)[O-])=CC=C(S(=O)(=O)C=2C(=CC(=CC=2)[N+]([O-])=O)CC(=O)C=2C=CC=CC=2)C=1CC(=O)C1=CC=CC=C1 YPAMEUJNJVCLNP-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 1
- VYNUATGQEAAPAQ-UHFFFAOYSA-N 2-sulfonylacetic acid Chemical compound OC(=O)C=S(=O)=O VYNUATGQEAAPAQ-UHFFFAOYSA-N 0.000 description 1
- KWVKOYBKUXUKDS-UHFFFAOYSA-N 3-(4-bromophenyl)-2-(2-chlorophenyl)sulfonyl-1-phenylprop-2-en-1-one Chemical compound ClC1=CC=CC=C1S(=O)(=O)C(C(=O)C=1C=CC=CC=1)=CC1=CC=C(Br)C=C1 KWVKOYBKUXUKDS-UHFFFAOYSA-N 0.000 description 1
- QAWBXYVZQVGZAP-UHFFFAOYSA-N 3-(4-bromophenyl)-2-(2-nitrophenyl)sulfonyl-1-phenylprop-2-en-1-one Chemical compound [O-][N+](=O)C1=CC=CC=C1S(=O)(=O)C(C(=O)C=1C=CC=CC=1)=CC1=CC=C(Br)C=C1 QAWBXYVZQVGZAP-UHFFFAOYSA-N 0.000 description 1
- NKEZKRHTIDOVSX-UHFFFAOYSA-N 3-(4-bromophenyl)-2-(4-chlorophenyl)sulfonyl-1-phenylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC=CC=1)=CC1=CC=C(Br)C=C1 NKEZKRHTIDOVSX-UHFFFAOYSA-N 0.000 description 1
- HKSMWZCEBDDOSD-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-(4-fluorophenyl)sulfonyl-1-phenylprop-2-en-1-one Chemical compound C1=CC(F)=CC=C1C=C(S(=O)(=O)C=1C=CC(F)=CC=1)C(=O)C1=CC=CC=C1 HKSMWZCEBDDOSD-UHFFFAOYSA-N 0.000 description 1
- JZLMLFCJWFMZMC-UHFFFAOYSA-N 3-phenylpropanethioic s-acid Chemical class SC(=O)CCC1=CC=CC=C1 JZLMLFCJWFMZMC-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- ATQYXMMYXOTCDA-JQBMIRIKSA-N C1=CC(Br)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(Br)=CC=1)/C=C\C1=CC=CC=C1 Chemical compound C1=CC(Br)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(Br)=CC=1)/C=C\C1=CC=CC=C1 ATQYXMMYXOTCDA-JQBMIRIKSA-N 0.000 description 1
- RXIAYSLAWGTXBE-JQBMIRIKSA-N C1=CC(Cl)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(Cl)=CC=1)/C=C\C1=CC=CC=C1 Chemical compound C1=CC(Cl)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(Cl)=CC=1)/C=C\C1=CC=CC=C1 RXIAYSLAWGTXBE-JQBMIRIKSA-N 0.000 description 1
- YHCMQPPHPAYPQM-JQBMIRIKSA-N C1=CC(F)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(F)=CC=1)/C=C\C1=CC=CC=C1 Chemical compound C1=CC(F)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(F)=CC=1)/C=C\C1=CC=CC=C1 YHCMQPPHPAYPQM-JQBMIRIKSA-N 0.000 description 1
- XJNHONCWGODPIZ-XSYHWHKQSA-N C=1C=CC=CC=1\C=C/S(=O)(=O)\C=C/C1=CC=CC=C1 Chemical class C=1C=CC=CC=1\C=C/S(=O)(=O)\C=C/C1=CC=CC=C1 XJNHONCWGODPIZ-XSYHWHKQSA-N 0.000 description 1
- 101100397595 Caenorhabditis elegans jnk-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 1
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- DNMCCXFLTURVLK-VAWYXSNFSA-N [(e)-2-(benzenesulfonyl)ethenyl]benzene Chemical compound C=1C=CC=CC=1S(=O)(=O)\C=C\C1=CC=CC=C1 DNMCCXFLTURVLK-VAWYXSNFSA-N 0.000 description 1
- MRTIWTGAGMZREP-VAWYXSNFSA-N [(e)-2-phenylethenyl]sulfonylmethylbenzene Chemical class C=1C=CC=CC=1/C=C/S(=O)(=O)CC1=CC=CC=C1 MRTIWTGAGMZREP-VAWYXSNFSA-N 0.000 description 1
- WZDKIPVHBCBPCR-QXMHVHEDSA-N [(z)-2-benzylsulfanylethenyl]benzene Chemical class C=1C=CC=CC=1CS\C=C/C1=CC=CC=C1 WZDKIPVHBCBPCR-QXMHVHEDSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- QXLPXWSKPNOQLE-UHFFFAOYSA-N methylpentynol Chemical compound CCC(C)(O)C#C QXLPXWSKPNOQLE-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical class BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- SNCHEDBJOUWPMJ-UHFFFAOYSA-M sodium;phenylmethanethiolate Chemical compound [Na+].[S-]CC1=CC=CC=C1 SNCHEDBJOUWPMJ-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/12—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Graft Or Block Polymers (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6093397P | 1997-10-03 | 1997-10-03 | |
| US60/060,933 | 1997-10-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000111513A RU2000111513A (ru) | 2002-05-10 |
| RU2201919C2 true RU2201919C2 (ru) | 2003-04-10 |
Family
ID=22032642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000111513/04A RU2201919C2 (ru) | 1997-10-03 | 1998-10-01 | Стирилсульфоновые соединения, фармацевтические композиции на их основе, способ ингибирования роста опухолевых клеток, способ индукции апоптоза опухолевых клеток и способ лечения |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6359013B1 (https=) |
| EP (1) | EP1027330B1 (https=) |
| JP (1) | JP4294217B2 (https=) |
| KR (1) | KR100579355B1 (https=) |
| CN (1) | CN1163480C (https=) |
| AT (1) | ATE284386T1 (https=) |
| AU (1) | AU741042B2 (https=) |
| BR (1) | BR9814059B1 (https=) |
| CA (1) | CA2305790C (https=) |
| CZ (1) | CZ299718B6 (https=) |
| DE (1) | DE69828079T2 (https=) |
| IL (1) | IL135438A (https=) |
| NZ (1) | NZ503479A (https=) |
| RU (1) | RU2201919C2 (https=) |
| WO (1) | WO1999018068A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548553B2 (en) | 1997-10-03 | 2003-04-15 | Temple University-Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
| US6762207B1 (en) | 1999-04-02 | 2004-07-13 | Temple University - Of The Commonwealth System Of Higher Education | (E)-styryl sulfone anticancer agents |
| EP1173160B1 (en) * | 1999-04-02 | 2005-06-22 | Temple University of the Commonwealth System of Higher Education | (e)-styryl sulfone anticancer agents |
| AU778825B2 (en) | 1999-06-16 | 2004-12-23 | Temple University - Of The Commonwealth System Of Higher Education | (Z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors |
| AU780844B2 (en) * | 1999-10-12 | 2005-04-21 | Temple University-Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| US6767926B1 (en) | 1999-10-12 | 2004-07-27 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| US6541475B2 (en) * | 2000-04-14 | 2003-04-01 | Temple University - Of The Commonwealth System Of Higher Education | α, β-unsaturated sulfones for treating proliferative disorders |
| US6486210B2 (en) | 2000-04-14 | 2002-11-26 | Temple University—Of the Commonwealth System of Higher Education | Substituted styryl benzylsulfones for treating proliferative disorders |
| WO2002028828A1 (en) * | 2000-10-05 | 2002-04-11 | Temple University - Of The Commonwealth System Of Higher Education | Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
| JP2004521126A (ja) | 2001-02-27 | 2004-07-15 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | （ｚ）−スチリルベンジルスルホン及びそれらの医薬としての使用 |
| AU2002305942B2 (en) | 2001-02-28 | 2006-10-26 | Onconova Therapeutics, Inc. | Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones |
| EP1534284B1 (en) * | 2002-02-28 | 2011-07-27 | Temple University - Of The Commonwealth System of Higher Education | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
| WO2003072062A2 (en) * | 2002-02-28 | 2003-09-04 | Temple University-Of The Commonwealth System Of Higher Education | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| JP5196787B2 (ja) * | 2003-11-14 | 2013-05-15 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 増殖性疾患を治療するためのα，β−不飽和スルホキシド |
| KR101274524B1 (ko) | 2004-03-16 | 2013-06-19 | 온코노바 테라퓨틱스, 인코포레이티드 | 증식성 질병 치료용 치환 페녹시- 및 페닐티오- 유도체 |
| EP1773310B9 (en) | 2004-06-24 | 2012-04-25 | Temple University - Of The Commonwealth System of Higher Education | Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof |
| US20090306207A1 (en) * | 2005-01-05 | 2009-12-10 | Reddy M V Ramana | Treatment of Drug-Resistant Proliferative Disorders |
| AU2006216544B2 (en) * | 2005-02-25 | 2012-04-05 | Onconova Therapeutics, Inc. | Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis |
| JP5278968B2 (ja) | 2006-08-30 | 2013-09-04 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法 |
| CA2663375A1 (en) * | 2006-09-15 | 2008-03-20 | Onconova Therapeutics, Inc. | Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions |
| WO2008076270A2 (en) * | 2006-12-13 | 2008-06-26 | Temple University-Of The Commonwealth System Of Higher Education | Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof |
| KR101992929B1 (ko) | 2012-09-20 | 2019-06-25 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 치환된 알킬 디아릴 유도체, 제조방법 및 용도 |
| WO2014089483A1 (en) | 2012-12-07 | 2014-06-12 | Onconova Therapeutics, Inc. | Methods and compositions for treatment of cancer |
| US10383831B2 (en) | 2015-08-03 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4937388A (en) * | 1985-08-09 | 1990-06-26 | Imperial Chemical Industries Plc | Insecticidal ethers |
| EP0398818A1 (fr) * | 1989-04-10 | 1990-11-22 | Rhone-Poulenc Agrochimie | Sulfones herbicides dihalogénées |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2532612A (en) | 1945-08-29 | 1950-12-05 | Union Oil Co | Preparation of unsaturated thio-ethers |
| US3185743A (en) | 1960-08-24 | 1965-05-25 | Union Carbide Corp | Production of olefinic compounds from allyl sulfones |
| US3418101A (en) | 1965-12-15 | 1968-12-24 | Pennsalt Chemicals Corp | Process for plant desiccation |
| US3514386A (en) | 1967-12-11 | 1970-05-26 | Exxon Research Engineering Co | Stereoselective addition of thiols to acetylenic compounds |
| US3917714A (en) | 1972-09-06 | 1975-11-04 | American Cyanamid Co | Bis(alkylsulfonyl)vinylbenzenes |
| US4161407A (en) | 1977-10-06 | 1979-07-17 | Eastman Kodak Company | Crosslinkable polymers having vinylsulfonyl groups or styrylsulfonyl groups and their use as hardeners for gelatin |
| US4386221A (en) | 1981-10-28 | 1983-05-31 | Eastman Kodak Company | Process for the preparation of aryl alkyl sulfones and aryl vinyl sulfones |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| WO1996040629A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders |
| US5659087A (en) | 1995-06-07 | 1997-08-19 | Eli Lilly And Company | Diarylvinyl sulfoxides |
-
1998
- 1998-10-01 AU AU95954/98A patent/AU741042B2/en not_active Ceased
- 1998-10-01 CN CNB988098199A patent/CN1163480C/zh not_active Expired - Fee Related
- 1998-10-01 IL IL13543898A patent/IL135438A/xx not_active IP Right Cessation
- 1998-10-01 DE DE69828079T patent/DE69828079T2/de not_active Expired - Lifetime
- 1998-10-01 NZ NZ503479A patent/NZ503479A/xx not_active IP Right Cessation
- 1998-10-01 JP JP2000514880A patent/JP4294217B2/ja not_active Expired - Fee Related
- 1998-10-01 EP EP98949680A patent/EP1027330B1/en not_active Expired - Lifetime
- 1998-10-01 US US09/509,227 patent/US6359013B1/en not_active Expired - Lifetime
- 1998-10-01 WO PCT/US1998/020580 patent/WO1999018068A1/en not_active Ceased
- 1998-10-01 AT AT98949680T patent/ATE284386T1/de not_active IP Right Cessation
- 1998-10-01 RU RU2000111513/04A patent/RU2201919C2/ru not_active IP Right Cessation
- 1998-10-01 BR BRPI9814059-0A patent/BR9814059B1/pt not_active IP Right Cessation
- 1998-10-01 CZ CZ20001174A patent/CZ299718B6/cs not_active IP Right Cessation
- 1998-10-01 CA CA002305790A patent/CA2305790C/en not_active Expired - Fee Related
- 1998-10-01 KR KR1020007003554A patent/KR100579355B1/ko not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4937388A (en) * | 1985-08-09 | 1990-06-26 | Imperial Chemical Industries Plc | Insecticidal ethers |
| EP0398818A1 (fr) * | 1989-04-10 | 1990-11-22 | Rhone-Poulenc Agrochimie | Sulfones herbicides dihalogénées |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1027330B1 (en) | 2004-12-08 |
| BR9814059A (pt) | 2000-09-26 |
| EP1027330A4 (en) | 2003-09-10 |
| IL135438A0 (en) | 2001-05-20 |
| IL135438A (en) | 2005-12-18 |
| CZ299718B6 (cs) | 2008-10-29 |
| NZ503479A (en) | 2002-08-28 |
| BR9814059B1 (pt) | 2010-08-24 |
| WO1999018068A1 (en) | 1999-04-15 |
| ATE284386T1 (de) | 2004-12-15 |
| CZ20001174A3 (cs) | 2000-09-13 |
| DE69828079D1 (de) | 2005-01-13 |
| CA2305790A1 (en) | 1999-04-15 |
| CA2305790C (en) | 2008-09-23 |
| US6359013B1 (en) | 2002-03-19 |
| CN1273580A (zh) | 2000-11-15 |
| DE69828079T2 (de) | 2005-12-22 |
| HK1031373A1 (en) | 2001-06-15 |
| KR20010015689A (ko) | 2001-02-26 |
| KR100579355B1 (ko) | 2006-05-12 |
| JP2001519326A (ja) | 2001-10-23 |
| EP1027330A1 (en) | 2000-08-16 |
| AU741042B2 (en) | 2001-11-22 |
| CN1163480C (zh) | 2004-08-25 |
| AU9595498A (en) | 1999-04-27 |
| JP4294217B2 (ja) | 2009-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2201919C2 (ru) | Стирилсульфоновые соединения, фармацевтические композиции на их основе, способ ингибирования роста опухолевых клеток, способ индукции апоптоза опухолевых клеток и способ лечения | |
| US6548553B2 (en) | Styryl sulfone anticancer agents | |
| US6201154B1 (en) | Z-styryl sulfone anticancer agents | |
| EP1305015B1 (en) | Substituted styryl benzylsulfones for treating proliferative disorders | |
| US6762207B1 (en) | (E)-styryl sulfone anticancer agents | |
| AU2001251615A1 (en) | Substituted styryl benzylsulfones for treating proliferative disorders | |
| EP1292308B1 (en) | Alpha,beta-unsaturated sulfones for treating proliferative disorders | |
| EP1173160B1 (en) | (e)-styryl sulfone anticancer agents | |
| EP1328511B1 (en) | Substituted (e)-styryl benzylsulfones for treating proliferative disorders | |
| WO2000059494A1 (en) | Styryl sulfone anticancer agents | |
| HK1031373B (en) | Styryl sulfone anticancer agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20161002 |